Healthcare

• VB0004 is a first-in-class oral antifibrotic compound with a completed Phase Ia safety and pharmacokinetic study.

• The test demonstrated sensitivity of 80.3% and specificity of 48.5% for Stage 0 to Stage 2 breast cancer in the validation study.

• The approval covers all study materials including the protocol and informed consent forms, enabling active site initiation.

Singular Health Group Ltd (ASX:SHG) develops digital healthcare technology solutions, including medical imaging platforms. The company’s latest announcement outlines a memorandum of understanding with Florida International University for a medical imaging data repository project supporting Florida Medicaid and details the proposed structure, funding and …

Tissue Repair Ltd (ASX:TRP) is a biotechnology company that has been listed on the Australian Securities Exchange. The company’s latest announcement relates to an off-market equal-access share buy-back and associated steps connected with its planned removal from the ASX official list.

Argent BioPharma Limited (ASX:RGT) is a biotechnology company focused on developing and commercialising healthcare products. The company’s latest announcement outlines an exclusive licence agreement with NLC Ltd. and Dr Dorit Arad covering Tollovir, Tollovid and NutraVir, including intellectual property rights, payment arrangements and future …

According to the company's ASX announcement, as published on its investor website, Peters Investments Pty Ltd has advanced A$3.5 million under a convertible note subscription agreement. Until the notes are issued, the money is treated as an interest-bearingLoanat 12.5% per annum, compounded monthly and …